El Camino Health announces its official adoption of FloPatch—a technology that monitors blood flow in real time—a year after initially collaborating with Fogarty Innovation and FloSonics Medical in a pilot program. Developed by FloSonics Medical, FloPatch is a wireless, wearable Doppler ultrasound system that reportedly aids clinicians with managing intravenous (IV) fluid therapy earlier in the sepsis care pathway.

FDA approved FloPatch continuously assesses blood flow in the carotid arteries.

Flosonics was first introduced to El Camino Health via Fogarty Innovation, a non-profit, educational, medical technology accelerator located at the hospital’s Mountain View campus. Flosonics participated in Fogarty Innovation’s Company Accelerator Program, a six-month cross-functional mentoring program that helps early-stage companies with their business model and lead them to progress toward key milestones.

“Timing is crucial when caring for patients with sepsis. Our nurses have seen firsthand how effective FloPatch is in monitoring the effectiveness of treatment in deteriorating patients, especially those with sepsis and low blood pressure,” said Cheryl Reinking, chief nursing officer at El Camino Health. “We are proud to be the first hospital in the world to adopt this advanced technology. Our nurses immediately loved it, and helped decide where in the hospital the technology would be the best fit.”

According to the organization, Mike Regan, chief innovation officer, and Zach Edmonds, MD, strategic advisor, the Flosonics team worked directly with clinicians at El Camino Health to gain a better understanding of the patient journey and determine the best clinical use for their new technology. Through this process, the Flosonics team reportedly focused on the unmet clinical need of more efficiently managing fluids in critically ill patients.

“We’re thrilled to partner with El Camino Health to launch this pioneering ultrasound technology,” commented Jon-Emile Kenny, MD, chief medical officer at Flosonics Medical. “FloPatch is more than an innovative ultrasound system, it is a new paradigm linking physiology and resuscitation medicine.”